The dual function transcription regulator with a dynamic activity of EZH2 suggests additional mechanism by which EZH2 promotes NSCLC progression and underscores the need for developing context-specific strategy for therapeutic targeting of EZH2 in NSCLC. This evidence concerns the gene EZH2 and non-small cell lung carcinoma.